Treatment of osteoporosis with denosumab in patients with decreased kidney function

Abstract

IntroductionLittle is known about treatment of osteoporosis with denosumab (Prolia®) in patients with decreased kidney function. The aim of this retrospective case report study was to investigate effects and side-effects of such treatment.MethodsSince 2012, 75 patients with osteoporosis and decreased kidney function had been treated with denosumab (Prolia®) in the osteoporosis outpatient clinic of the department of endocrinology, Bispebjerg Hospital, University of Copenhagen, Denmark, and data were retrospectively collected from the patient records of these patients in 2021.ResultsAt baseline, the mean estimated glomerular filtration rate (eGFR) was 34 mL/min (range 9–50) and the median age was 85 years (range 45–103). 95% of the patients had had low-energy fractures, and the bone mineral density T score of the hips was on average − 2.7. All, but one, patients had normal/high parathyroid hormone (PTH) levels.The mean duration of the treatment with denosumab at the follow-up was 5.3 years (range 1.5–10). There was an annual increase of 12% and of 7% in the T score of in the lumbar spine and hip, respectively, compared to the T-scores prior to the denosumab treatment. 20% had a new fracture during the follow-up. 21% had biochemical hypocalcemia following denosumab injection, 7% developed symptoms of hypocalcemia, whereas 4% needed to be hospitalized acutely.ConclusionTreatment with denosumab of osteoporosis in patients with decreased kidney function (eGFR 9–50 mL/min), with normal/high PTH, seems in general to be well tolerated, with improvement of bone and decreased risk of new fractures.